Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single arm, randomised, placebo control, Phase 3 study of bexobrutideg in relapsed/refractory CLL patients compared to an investigator's choice control arm consisting of bendamustine and rituximab, idelalisib and rituximab, or pirtobrutinib

Next Previous
Trial Profile

A single arm, randomised, placebo control, Phase 3 study of bexobrutideg in relapsed/refractory CLL patients compared to an investigator's choice control arm consisting of bendamustine and rituximab, idelalisib and rituximab, or pirtobrutinib

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexobrutideg (Primary) ; Bendamustine; Idelalisib; Pirtobrutinib; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Nurix

Most Recent Events

  • 13 Nov 2025 New trial record
  • 22 Oct 2025 According to Nurix media release,company plans to initiate a randomized confirmatory Phase 3 trial in the first half of 2026 in r/r CLL patients whose disease has previously progressed while receiving a cBTKi. This global Phase 3 confirmatory trial in patients treated in the second line or later setting will compare bexobrutideg monotherapy to an investigators choice of pirtobrutinib monotherapy (a ncBTKi), bendamustine plus rituximab, or idelalisib plus rituximab.
  • 09 Oct 2025 According to Nurix medi release, the company plans for the trial initiation in fourth quarter of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top